SCHEMBL5680340

SCHEMBL5680340

CC(C)(C)C(CCCO)(SCc1ccccc1)C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
PRMT1 Q99873 1/20 0.46
TDP1 Q9NUW8 2/20 0.35
IDO1 P14902 3/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
ALDH1A1 P00352 2/20 0.34
TSHR P16473 1/20 0.33
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
TAAR1 Q96RJ0 2/20 0.32
SLC6A2 P23975 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7796812 0.75 CYP2D6 (0.61) CYP1A2CYP3A4CYP2D6PRMT1TDP1
SCHEMBL6944777 0.71 CYP2D6 (0.47) CYP1A2CYP3A4CYP2D6PRMT1IDO1
SCHEMBL6832085 0.70 CYP3A4 (0.46) CYP1A2CYP3A4CYP2D6PRMT1TDP1
SCHEMBL2655561 0.70 CYP1A2 (0.59) CYP1A2CYP3A4CYP2D6PRMT1TDP1
SCHEMBL5680420 0.69 CYP2D6 (0.63) CYP1A2CYP3A4CYP2D6PRMT1IDO1
SCHEMBL28924913 0.69 SLC6A2 (0.47) CYP1A2CYP3A4CYP2D6TDP1ALDH1A1
Bromide SCHEMBL20854775 0.69 CYP1A2 (0.57) CYP1A2CYP3A4CYP2D6PRMT1TDP1
SCHEMBL6447334 0.68 CYP1A2 (0.43) CYP1A2CYP3A4CYP2D6PRMT1TDP1
SCHEMBL11413592 0.67 CYP2C19 (0.55) CYP1A2CYP3A4CYP2D6TDP1IDO1
SCHEMBL13348421 0.67 CYP2D6 (0.46) CYP1A2CYP3A4CYP2D6PRMT1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1497268-A4 NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2006-01-18 EP disclosed
EP-1497268-A2 NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-01-19 EP disclosed
US-20030203915-A1 Nitric oxide donors, compositions and methods of use related applications NICOX S.A. (FR) 2003-10-30 US disclosed
WO-2003086282-A2 NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203915-A1 Nitric oxide donors, compositions and methods of use related applications NOS1, NOS2, NOS3 CYP1A2 514/4885CYP3A4 984/4885CYP2D6 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.